On August 7th 2019 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, announced the publication of pre-clinical data showing the company’s PIM/PI3K/mTOR, AUM302 (formerly IBL-302), has promise as a treatment for neuroblastoma (Press release, Inflection Biosciences, AUG 7, 2019, View Source [SID1234538591]). This research has recently been published in the medical journal EMBO Molecular Medicine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This publication is the result of a collaboration between Inflection Biosciences and two research teams at the Lund University Cancer Centre, Sweden, led by Associate Professors Sofie Mohlin and Daniel Bexell. Inflection Biosciences recently announced that global development and commercialisation rights to AUM302 were granted to AUM Biosciences, Singapore.
Neuroblastoma is an extracranial childhood malignancy of the nervous system that accounts for 15% of all paediatric cancer fatalities. Despite advances in treatment, children with high‐risk disease have poor survival rates, with up to 40% 5‐year mortality. It has previously been shown that targeting the PI3K/mTOR pathway could be a viable treatment for aggressive neuroblastoma. Furthermore, in neuroblastoma cell lines and patient derived xenograft (PDX) derived cell cultures, high levels of PIM were also significantly associated with adverse neuroblastoma patient outcomes.
These published results show that from a panel of 707 cell lines across 47 tumour types, neuroblastoma was the most sensitive tumour type to AUM302 treatment, and out of 16 neuroblastoma cell lines, AUM302 was generally more effective than PI3K inhibitors alone. AUM302 improved the effect of three clinically used chemotherapeutic agents in vitro. AUM302 treatment alone reduced tumour growth in a neuroblastoma xenograft and inhibited neuroblastoma PDX growth in combination with low‐dose cisplatin.
Dr. Bexell, one of the lead authors on the publication, commented: "Adding AUM302 to current treatments to lower administered doses of highly toxic chemotherapy could decrease complications later in life and improve outcomes in these young neuroblastoma patients."
The publication titled ‘Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma’ can be accessed here.
The research was funded by the Swedish Cancer Society and the Swedish Childhood Cancer Foundation.